BioSpace News Archive

Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced its participation in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the signing of a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD 780 million in cash.

Cue Health (“Cue”) (Nasdaq: HLTH), today announced it will develop an Omicron-Genotyping COVID-19 test to be used in professional point-of-care settings as part of the company’s ongoing work with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), today announced that preclinical data successfully established proof of concept in two key areas of cell-based gene therapy – skin rejuvenation and epidermolysis bullosa.

Timber Pharmaceuticals, Inc. announced that John Koconis, Chairman and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect Virtual Conference being held on January 10-13, 2022.

Cidara Therapeutics, Inc. announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 17,000 shares of its common stock to three new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date of December 31, 2021.

Aristea Therapeutics, a clinical-stage immunology focused drug development company developing novel therapies to treat rare serious inflammatory diseases, announced that James Mackay, Ph.D., President and CEO, will participate virtually in the following investor conferences in January.

Eiger BioPharmaceuticals, Inc. today provided the company’s outlook across multiple pipeline programs and operations, including planned 2022 catalysts and milestones.

Aldeyra Therapeutics, Inc., a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference.

Horizon Therapeutics plc announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. to be the first tenant at the Alexandria Center® at Traville Gateway campus in Rockville, Maryland.